Ondine Biomedical, Inc. (OBI) Stock Statistics & Valuation Metrics

Ondine Biomedical, Inc. has a market cap or net worth of £60.94M. The enterprise value is 221.77M.

Ondine Biomedical, Inc. has 443,233,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ondine Biomedical, Inc.’s return on equity (ROE) is -6.91 and return on invested capital (ROIC) is -563.79%.

The current PE Ratio of Ondine Biomedical, Inc. is -2.02. Ondine Biomedical, Inc.’s PEG ratio is 0.92.

In the last 12 months, Ondine Biomedical, Inc. had revenue of 1.20M and earned -14.41M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was ― and capital expenditures 0.00, giving a free cash flow of ― billion.

Ondine Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ondine Biomedical, Inc. upcoming earnings date is ―, ―.

Ondine Biomedical, Inc. as a current ratio of 1.36, with Debt / Equity ratio of -107.61%

In the past 12 months, Ondine Biomedical, Inc. has paid 0.00 in taxes.

Ondine Biomedical, Inc. EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -1.93.

Ondine Biomedical, Inc. has £2.98M in cash and marketable securities with C$541.00K in debt, giving a net cash position of -£2.44M billion.

Gross margin is 29.31%, with operating margin of -1230.67%, and net profit margin of -1198.00%.

The average price target for Ondine Biomedical, Inc. is £55.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy